Eli Lilly and vs Euro/US Dollar FX Spot Rate: why the prices moved differently

• ▲

  Foundayo captures one-third of new oral GLP-1 patients Lilly's oral weight-loss pill Foundayo now accounts for about one-third of new patients starting oral GLP-1 medicines, with market share rising weekly. This shows real commercial traction, supporting future sales growth and reinforcing Lilly's obesity franchise.

  Demonstrates Foundayo's rapid adoption, a key growth driver for Lilly's obesity business.

• ▲

  Retatrutide delivers up to 20.8% weight loss in Phase 3 Lilly's next-generation obesity drug retatrutide helped patients lose up to 20.8% of body weight in a Phase 3 trial, with many no longer meeting obesity criteria. This strengthens Lilly's pipeline and future growth prospects beyond current drugs.

  Positive clinical data for a key pipeline asset boosts long-term revenue potential.

• ▲

  Foundayo cuts cardiovascular risk in large trial Foundayo reduced heart risks by 16% versus insulin in a major trial, with lower death rates. This could expand its use to heart patients, boosting sales and differentiating it from competitors.

  Cardiovascular benefit expands Foundayo's label potential and market reach.

• ▼

  Novo's CagriSema beats Lilly's tirzepatide in head-to-head Novo Nordisk's CagriSema helped patients lose 12.4% weight versus 9.1% for Lilly's tirzepatide in a Phase 3 trial. This competitive threat could slow Lilly's market share gains if CagriSema wins approval.

  Direct competitive loss in a key trial poses a risk to Lilly's obesity leadership.

Based on 6 stories →

• ▲

  FDA approves new breast cancer combo The FDA granted full approval to Lilly's Inluriyo plus Verzenio for ESR1-mutated breast cancer, based on a trial where the combo doubled progression-free survival versus Inluriyo alone. This expands Lilly's oncology offerings and adds a new revenue stream, helping diversify beyond obesity drugs.

  New approval directly boosts Lilly's oncology business and revenue potential.

• ▲

  Lilly breaks ground on $6.5B Houston plant Lilly started building a $6.5 billion manufacturing site in Houston to produce active ingredients for its medicines, including the oral obesity drug Foundayo. This is part of a $50 billion U.S. investment to expand capacity and secure supply for future growth.

  Major capital investment supports long-term production capacity and supply chain.

• ▼

  Novo's CagriSema beats Zepbound in head-to-head trial In a phase 3 trial, Novo's CagriSema helped patients lose 12.4% of their weight over 60 weeks, compared to 9.1% for Lilly's Zepbound. This suggests a competitive threat in the obesity market, potentially slowing Lilly's market share gains if CagriSema wins approval.

  Direct competitive trial result could pressure Lilly's obesity franchise.

• ▲

  FDA approves once-weekly insulin Onswik The FDA approved Lilly's Onswik, a once-weekly basal insulin for type 2 diabetes, which cuts injections from daily to weekly. This strengthens Lilly's diabetes portfolio and offers a more convenient option, potentially capturing market share from daily insulins.

  New product approval expands diabetes franchise and addresses patient convenience.

Based on 14 stories →

• ▲

  Foundayo grabs 30% of new US oral weight-loss patients Lilly's new obesity pill Foundayo has captured over 30% of new US patients starting oral weight-loss medicines, up from almost nothing. Novo's Wegovy pill once held about 90% of that market. This shows Lilly is winning real prescriptions, not just headlines, which supports future sales.

  Concrete evidence that Lilly's newest product is taking market share, a key growth driver.

• ▲

  Citi raises Lilly target to Street-high $1,600 Citi lifted its Lilly price target to $1,600, implying about 45% upside, even after the stock fell 8% in a month. The analyst points to Lilly's dominance in obesity prescriptions, Foundayo's prescriber growth, and retatrutide's strong trial results. This boosts investor confidence.

  A major analyst upgrade directly addresses why the stock could move higher despite recent weakness.

• ▲

  Lilly completes AtaiBeckley deal for depression drug Lilly closed its acquisition of AtaiBeckley, adding BPL-003, a rapid-acting treatment for depression that resists standard therapy. This expands Lilly's neuroscience pipeline beyond obesity, using its cash to plant seeds for future growth. It reduces reliance on weight-loss drugs.

  Shows Lilly is actively diversifying into new treatment areas, a strategic positive.

• ▲

  New data and deals bolster pipeline at EASD and beyond Lilly will present strong trial data for retatrutide, Foundayo, and eloraTZP at a major diabetes conference. It also signed new research deals with QurCan and Twist Bioscience. These moves strengthen Lilly's pipeline and technology, supporting long-term growth even if they don't boost sales immediately.

  Highlights ongoing pipeline progress and partnerships that underpin future revenue.

Based on 13 stories →

• ▲

  Lilly hits $1 trillion market cap on obesity drug strength Lilly crossed $1 trillion in market value, with Q2 revenue up 47.7% and Mounjaro sales up 91%. The obesity franchise and expanded access are powering growth, and analysts see more upside.

  This milestone reflects the scale of Lilly's success and investor confidence, directly answering why the stock is moving.

• ▲

  J.P. Morgan raises estimates on obesity drug growth J.P. Morgan lifted 2027 revenue and EPS forecasts, keeping an Overweight rating and $1,400 target. It expects incretin sales to exceed $100 billion by 2030, driven by Zepbound, Mounjaro, and Foundayo.

  Analyst upgrades signal growing confidence in Lilly's long-term growth, a key driver of stock movement.

• ▲

  Lilly launches Foundayo in UK, first European market Lilly launched its oral weight-loss pill Foundayo in the UK, the first European market. The pill costs £100-£120 per month, much less than injections, potentially widening access and boosting sales.

  This is a concrete step in expanding Lilly's obesity franchise globally, directly supporting future revenue growth.

• ▲

  Lilly builds neuroscience as new growth driver Neuroscience revenue grew 32% to $811 million in H1 2026, led by Kisunla. Acquisitions like AtaiBeckley and Centessa add pipeline assets, diversifying beyond obesity and reducing reliance on GLP-1 drugs.

  This shows Lilly's efforts to create a second growth engine, which could sustain long-term growth and attract investors.

Based on 11 stories →

• ▲

  FDA expands Mounjaro label to cut heart risks The FDA approved Mounjaro to lower the risk of heart attacks, strokes and heart-related death in high-risk type 2 diabetes patients. This makes the drug useful for more people, supporting sales and pricing power, though it also increases pressure on manufacturing capacity and insurance coverage.

  A new regulatory approval directly expands the market for Lilly's biggest drug.

• ▲

  Taltz plus Zepbound shows durable one-year benefit Phase 3b trials showed combining Taltz and Zepbound helped patients with psoriatic disease and obesity achieve clearer skin and more weight loss than Taltz alone after a year. This supports using Lilly drugs together, which could boost sales across both products.

  New clinical data supports broader use of two Lilly drugs together.

• ▲

  Lilly buys Merida Biosciences for up to $2.875 billion Lilly agreed to buy Merida Biosciences for up to $2.875 billion, gaining an early-stage immunology drug for Graves' disease and thyroid eye disease. This uses cash from Lilly's obesity franchise to diversify into new treatment areas, though the drug is still years from market.

  A major acquisition shows Lilly using its cash to build new growth beyond weight-loss drugs.

• ▼

  Novo launches oral Wegovy in Germany as competition builds Novo Nordisk launched its Wegovy pill in Germany, the EU's largest drug market, and expects pills to take over a third of GLP-1 use by 2030. Lilly's Foundayo pill is in Britain and targeting 40+ markets, so this is a real race for the oral obesity market.

  A direct competitor's launch in a key market threatens Lilly's share of the growing oral GLP-1 market.

Based on 8 stories →

• ▲

  Zepbound shown to cut healthcare costs in older adults A real-world study found Zepbound users over 55 had up to 38% lower healthcare costs, with savings reaching $607 per patient per month by 12 months. This evidence could persuade Medicare and insurers to cover obesity drugs, supporting demand.

  This new study directly addresses payer resistance, a key risk, by showing cost savings that could expand coverage and demand.

• ▼

  14% of US employers to drop obesity drug coverage by 2027 A survey shows about 14% of US employers plan to end GLP-1 coverage by 2027 due to rising costs, with the share covering obesity drugs already falling from 72% to 60%. This could reduce Zepbound prescriptions and slow US sales growth.

  This is a new, concrete threat to demand from a major payer group, directly countering the positive coverage narrative.

• ▲

  FDA clears Lilly-Roche Alzheimer's blood test The FDA cleared the Elecsys pTau217 blood test, developed with Roche, as the first single-biomarker test to rule in or out Alzheimer's amyloid pathology. This could expand diagnosis and boost the market for Lilly's Alzheimer's drug donanemab.

  This new approval opens a path to wider Alzheimer's diagnosis and treatment, a potential new growth area beyond GLP-1 drugs.

• ▲

  Oncology portfolio grows 11%, diversifying beyond GLP-1 Lilly's oncology revenue rose 11% to $4.84 billion in the first half, with newer drugs like Jaypirca up 66% and Inluriyo contributing $110 million. This shows Lilly is building a second growth engine, reducing reliance on obesity drugs.

  This new data highlights a broadening revenue base, which is important for long-term growth and risk reduction.

Based on 15 stories →

• ▲

  UK approves Foundayo for weight loss and diabetes Britain cleared Lilly's once-daily weight-loss pill Foundayo for both obesity and type 2 diabetes, the first European approval. A pill is easier for patients than injections, so it opens a new market and widens Lilly's lead over Novo's rival pill.

  New regulatory approval expands Lilly's addressable market and competitive position.

• ▲

  Lilly adds Alzheimer's and ion channel deals Lilly bought rights to an early-stage Alzheimer's drug for $10 million upfront (up to $1 billion more if it works) and teamed up with OmniAb on an ion channel program worth up to $370 million. These small bets refill the pipeline beyond weight-loss drugs.

  New deals diversify Lilly's pipeline and reduce reliance on GLP-1s.

• ▲

  Lilly partners on RNA vaccines Lilly signed a research and licensing deal with Amplitude Therapeutics to develop trans-amplifying RNA vaccines for infectious diseases, with options for two more targets. It is an early-stage move into a new treatment area, using Lilly's cash to plant seeds for future growth.

  New collaboration expands Lilly's technology base into vaccines.

• ▼

  Novo CEO says obesity market won't be winner-take-all Novo Nordisk's chief said the obesity market will split among many players, like different soda brands, rather than one winner. Novo's oral Wegovy already holds 90% of the oral GLP-1 market. This is a reminder that Lilly's dominance may face limits as competition grows.

  A real counterweight: competition could cap Lilly's long-term market share.

Based on 12 stories →

• ▲

  UK approves Foundayo, first market outside US Britain's regulator cleared Lilly's once-daily weight-loss pill Foundayo, the first approval outside the US. This opens a new market for a pill version of its obesity drug, which could reach patients who dislike injections. It is not yet sold through the NHS while cost regulators review it.

  A brand-new regulatory approval expands Lilly's addressable market beyond the US.

• ▲

  Amazon and CVS widen cheap access to Lilly drugs Amazon Pharmacy will offer Lilly's Zepbound pen and Foundayo pill to Medicare patients for $50 a month, and CVS expanded its weight-management program with Lilly, adding app-based access and $29 clinic visits. Easier, cheaper access should lift prescription volumes.

  New distribution deals directly increase how many patients can get Lilly's drugs.

• ▲

  Lilly sues sellers of unapproved retatrutide Lilly filed six lawsuits against businesses selling unapproved versions of retatrutide, its experimental obesity drug, and has referred over 200 parties to authorities. This protects the future franchise from unsafe copycats and keeps the market ready for the real drug when approved.

  Legal action defends a key future growth driver from illicit competition.

• ▲

  Analysts raise targets on international obesity opportunity BofA lifted its Lilly price target to $1,344 and said overseas obesity sales could eventually beat the US, with most Foundayo peak sales expected abroad. Other banks also raised targets after strong Q2 results. This reflects growing confidence in Lilly's global growth runway.

  Analyst upgrades signal that the market sees more upside from international expansion.

Based on 19 stories →

• ▲

  Q2 beat and raised guidance Lilly reported Q2 revenue of $22.97 billion, up 47.7%, and adjusted EPS of $8.38, beating estimates by 27%. Management raised full-year revenue guidance to $85–$87 billion and EPS to $36.25. The stock jumped as much as 7% on the news, reflecting strong demand for its obesity and diabetes drugs.

  This is the core new event that directly answers why LLY is moving right now.

• ▲

  Mounjaro and Zepbound sales surge Mounjaro sales jumped 91% to $9.94 billion and Zepbound brought in $4.93 billion, together 65% of total revenue. This shows Lilly's GLP-1 franchise is still growing rapidly, driving the earnings beat and giving confidence that demand remains strong despite competition.

  It explains the fundamental driver behind the beat-and-raise and the stock's move.

• ▲

  Novo Nordisk's setback boosts Lilly's competitive edge Novo Nordisk's next-generation obesity drug CagriSema fell short of Lilly's Zepbound in blood sugar control, and Novo guided to a sales decline and cut 9,000 jobs. This strengthens Lilly's position as the clear leader in the obesity market, which supports its pricing power and long-term growth.

  It highlights a key competitive shift that benefits Lilly and is new information.

• ▲

  Retatrutide filing planned for early 2027 Lilly plans to file for approval of its next-generation obesity drug retatrutide in early 2027. The drug helped patients lose over 20% of body weight and could also treat sleep apnea and reduce heart risk. Analysts see it as a future growth driver, though it won't contribute revenue until after 2027.

  It is a new pipeline update that reinforces Lilly's long-term growth story.

Based on 10 stories →

• ▲

  Q1 revenue surges 55.5% on Foundayo launch Lilly's first-quarter revenue jumped 55.5% to $19.8 billion, beating estimates, as new oral GLP-1 Foundayo and strong Mounjaro and Zepbound sales drove growth. Management raised full-year guidance, and an analyst set a $1,365 price target, reinforcing confidence in Lilly's earnings power.

  This shows the core financial engine behind Lilly's stock and why analysts remain bullish.

• ▲

  Retatrutide Phase 3 success, FDA filing planned Lilly's next-generation obesity drug retatrutide cut weight by up to 22.6% in Phase 3 trials, with a planned FDA submission in early 2027. This strengthens Lilly's future obesity franchise, though a slight imbalance in serious heart events bears watching.

  It confirms a major future growth driver and addresses the earlier delay, showing the pipeline is back on track.

• ▲

  Lilly expands US manufacturing with Resilience Lilly and Resilience are investing $750 million to expand U.S. production of the KwikPen injectable device, creating 400 jobs and boosting supply capacity for diabetes and obesity medicines. This helps ensure Lilly can meet soaring demand and reduces reliance on foreign manufacturing.

  It directly addresses supply constraints that could limit growth and shows Lilly investing in its core business.

• ▲

  Lilly joins Illumina's AI drug discovery alliance Lilly became a foundational participant in Illumina's Billion Cell Atlas, gaining access to massive genetic data to speed AI-driven drug discovery. This long-term move could help diversify Lilly's pipeline beyond GLP-1 drugs and keep it at the forefront of biotech innovation.

  It signals a strategic push into next-generation technology that could yield new drugs and reduce reliance on one franchise.

Based on 10 stories →

• ▲

  Lilly to buy AtaiBeckley for up to $3.8B Lilly agreed to pay $2.8 billion upfront, plus up to $1 billion more if milestones are met, for AtaiBeckley and its experimental psychedelic depression treatment. It uses Lilly's cash to add a new growth area beyond weight-loss drugs, though the upfront cost is real.

  This is the period's biggest new deal and shows how Lilly is spending its obesity-drug profits to diversify.

• ▼

  Retatrutide approval filing delayed to early 2027 Lilly pushed back its filing for next-generation obesity drug retatrutide because it needs more manufacturing and quality-control data for regulators. The drug still worked well in trials, but the delay means a key future growth driver arrives later than expected.

  This is the main new negative and directly affects Lilly's next big obesity-drug opportunity.

Based on 6 stories →

• ▼

  Germany's cost reform raises rebates, Lilly to scale back manufacturing Germany passed a law forcing drugmakers to pay higher rebates, aiming to cut €16 billion in health costs. Lilly's CEO said the company will scale back manufacturing plans there, a real headwind for its European business and investment.

  A concrete regulatory setback that could hurt Lilly's sales and expansion in a major market.

• ▲

  Lilly acquires AtaiBeckley for up to $3.8 billion Lilly is buying psychedelic drugmaker AtaiBeckley for about $2.8 billion upfront plus up to $1 billion in milestones. This adds a promising treatment for resistant depression to Lilly's pipeline, showing it is using its cash to expand beyond weight-loss drugs.

  A new strategic move that broadens Lilly's pipeline and signals long-term growth ambitions.

• ▼

  Novo Nordisk wins EU approval for oral Wegovy Novo Nordisk got EU clearance for the first oral GLP-1 pill for weight management, giving patients a pill option alongside injections. This intensifies competition for Lilly's obesity drugs in Europe, where pill preference could shift market share.

  A direct competitive threat in the key obesity market that could pressure Lilly's growth.

Based on 6 stories →

• ▲

  JPMorgan raises price target to $1,400, stock hits record JPMorgan lifted its LLY target from $1,300 to $1,400 and reiterated overweight, citing strong demand for Mounjaro and Zepbound. The stock hit an all-time high above $1,200, with market cap surpassing $1.1 trillion. Analyst expects Q2 earnings to beat consensus.

  This is a new analyst action that directly boosted the stock and reflects confidence in future growth.

• ▲

  Lilly presents Alzheimer's data at AAIC 2026 Lilly will present 16 abstracts at the Alzheimer's conference, including new data on its Kisunla treatment and a P-tau217 blood test that could simplify diagnosis. This advances its pipeline beyond obesity, offering another long-term growth driver.

  This is a new pipeline update that shows Lilly's broader research strength beyond weight-loss drugs.

• ▲

  Canada backs Lilly's eczema drug Ebglyss Canada's drug agency gave a positive recommendation for Lilly's eczema treatment Ebglyss, which could lead to public reimbursement and wider patient access. Ebglyss is already approved in Canada and other countries, and this expands its reach.

  This is a new regulatory win that broadens Lilly's revenue base beyond obesity and diabetes.

Based on 15 stories →

• ▲

  Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.

  This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.

• ▲

  Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.

  New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.

• ▲

  Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.

  Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.

• ▲

  Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.

  Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.

Based on 9 stories →

• ▼

  French debt crisis and political gridlock sink euro Investors are dumping French bonds and stocks as public debt heads toward 120% of GDP, pushing the French-German bond spread to 141 basis points. This political and fiscal risk makes the euro less attractive, pushing EURUSD down to its lowest since May 2025.

  This is the main new force driving the euro lower this period.

• ▼

  US bond yields surge, Fed rate hike bets rise US 10-year Treasury yields jumped above 5.2%, the highest since 2002, as oil prices climbed and Fed officials backed further rate hikes. Higher US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down.

  This is a key new driver of dollar strength this period.

• ▲

  Eurozone inflation beats forecasts, keeping ECB hike pressure alive Eurozone September inflation rose to 3.8%, above the 3.6% forecast, with core inflation up to 2.5%. This keeps pressure on the ECB to raise rates further, which supports the euro by attracting global money into euro deposits.

  This is a new counterweight that could support the euro despite the negative drivers.

• ▼

  Energy shock and political risk weigh on euro outlook European gas prices above €80/MWh and the war in Iran disrupting LNG shipments are hurting Europe's economy. Meanwhile, far-right gains in Germany and France's political gridlock add uncertainty. These factors make the euro less attractive, pushing EURUSD down.

  This explains the broader negative backdrop for the euro this period.

Based on 8 stories →

• ▲

  Eurozone economy unexpectedly strong, supports euro The eurozone's business activity index jumped to 53.1 in September, the highest in over three years, beating expectations. A stronger economy makes the euro more attractive and supports further ECB rate hikes, pushing EURUSD up.

  This is new data showing eurozone resilience, which strengthens the euro.

• ▲

  ECB officials hint at more rate hikes to fight inflation ECB's Nagel said rates may need to become restrictive, and Makhlouf said the ECB would act if energy prices spill over. BofA expects a December hike. Higher expected euro rates attract global money, pushing EURUSD up.

  New hawkish comments from ECB officials and BofA's forecast reinforce expectations of higher euro rates.

• ▼

  US bond yields surge and Fed officials back more hikes The 10-year US Treasury yield rose above 5%, the highest in 19 years, after strong US business activity data. Fed's Collins, Musalem, and Barr supported further rate hikes. Higher US rates make the dollar more attractive, pushing EURUSD down.

  New US data and Fed comments drive dollar strength, a key counterweight to the euro.

• ▼

  German political risk and ECB's Lane downplays wage pressure Germany's far-right party won a major regional election, weakening the coalition and raising political uncertainty. ECB's Lane said no strong wage pressure, suggesting fewer hikes. These factors weigh on the euro, pushing EURUSD down.

  New political and monetary developments that could undermine euro strength.

Based on 11 stories →

• ▲

  Markets price more ECB hikes; banks see 2.75% or higher Money markets now price more than four additional ECB hikes, and banks like Barclays, Goldman and Rabobank expect another 25bp move in December to 2.75%. Expectations of higher-for-longer euro rates attract foreign capital into the euro, supporting EURUSD.

  Shows how far investors expect euro rates to rise, a key support for the euro.

• ▼

  Fed hikes to 3.75-4.00%, first rise in three years The Fed raised rates on September 16, six days after the ECB, and strong US retail sales and 3.4% inflation backed the move. Higher US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down to about 1.1450.

  The Fed's hike is the main new force pulling EURUSD down this period.

• ◆

  Oil and gas above ECB assumptions keep inflation high Brent above $100 and natural gas above €83/MWh exceed the ECB's worst-case assumptions, so inflation may stay high longer. This keeps the ECB tightening, which supports the euro, but high energy also hurts Europe's growth and can push investors to the dollar.

  Energy prices are the underlying force driving both ECB tightening and euro weakness.

Based on 24 stories →

• ▲

  ECB delivers first hike in two meetings, signals more The ECB raised its deposit rate to 2.50% on September 10, its second hike this year, and said inflation will stay above target through 2028. Higher euro interest rates attract global money into the euro, pushing EURUSD up. Markets now expect at least one more hike by year-end.

  The ECB's actual rate hike and further-hike signal is the main new force lifting the euro.

• ▲

  Eurozone economy resilient, ECB raises growth forecast ECB President Lagarde said she was surprised by the economy's resilience, with defense, infrastructure and AI investment supporting growth. The ECB raised its 2026 growth forecast to 0.9%. A stronger economy makes the euro more attractive and supports further rate hikes, pushing EURUSD up.

  Economic resilience gives the ECB room to keep rates high, reinforcing euro strength.

• ▼

  US rate-hike odds jump on hot PPI, capping euro US producer price inflation rose 5.4% in August, above expectations, and markets now price a 70% chance of a Fed hike on September 16, up from 61%. Higher expected US rates make dollar deposits more attractive, strengthening the dollar and limiting EURUSD's rise.

  This is the main counterweight: US rate expectations are rising too, which caps the euro's gains.

• ▲

  Oil above $100 fuels inflation, keeping ECB hawkish Brent crude surged past $105 as Middle East conflict cut energy exports, pushing eurozone inflation to 3.3%. The ECB hiked to prevent energy costs spreading. While high oil can hurt growth, it keeps the ECB tightening, which supports the euro against the dollar.

  Oil-driven inflation is the reason the ECB is hiking, directly linking energy prices to euro strength.

Based on 7 stories →

• ▲

  Eurozone inflation jumps, ECB hike bets build Eurozone inflation rose to 3.3% in August from 2.9%, driven by energy, and producer prices jumped 5.8%. Officials like Holzmann and Nagel pushed for more tightening, and markets now price a September ECB hike with near certainty. Higher expected euro interest rates pull global money into the euro, pushing EURUSD up.

  Rising euro-area inflation and hawkish ECB signals are the main new force lifting the euro.

• ▲

  Banks see ECB hiking further, rates staying higher JPMorgan and BNP Paribas now expect an extra ECB hike in December, and DBS sees the deposit rate at 2.50%, citing sticky inflation and resilient growth. Expectations of higher-for-longer euro rates attract foreign capital into the euro, supporting EURUSD.

  New forecasts of further ECB tightening extend the rate advantage that supports the euro.

• ▼

  US euro-selling intervention and Fed pushback weigh on euro European central bankers are frustrated that the US sold euros to buy yen without warning, and Bundesbank's Nagel called it a surprise. The extra euro supply weakens the euro. Meanwhile, Fed's Waller backed holding US rates, and strong August US jobs raised hike odds, both supporting the dollar and pushing EURUSD down.

  This is the main counterweight: US policy actions and data that strengthen the dollar against the euro.

• ◆

  ECB's blockchain euro plan could support long-term demand ECB's Schnabel pushed for issuing a blockchain-based euro, rejecting stablecoins, with the Pontes project launching next month. If it makes the euro more useful in digital finance, it could gradually raise demand for euros. But the effect is long-term and small for now, so it is a minor support.

  A new structural initiative that could affect future euro demand, though not an immediate price driver.

Based on 12 stories →

• ▲

  ECB September rate hike increasingly expected The ECB is set to raise its policy rate to 2.50% in September to stop war-driven energy inflation spreading, and official Schnabel said more tightening is needed. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

  A near-certain ECB hike is the main force lifting the euro this period.

• ▼

  Fed Chair Warsh hints at a US rate hike At Jackson Hole, Fed Chair Warsh said there is 'work to do' on inflation, lifting the chance of a September US hike to about 57.5% from 35%. Higher expected US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down.

  This is the main new counterweight that pulled the euro back from its highs.

• ▼

  Hot US inflation surprise supports the dollar A hotter-than-expected US PCE inflation reading on August 27 pushed US rates and the dollar up, sending EURUSD to about 1.1650. Stronger US inflation keeps the Fed from easing, which supports the dollar and weighs on the euro.

  It shows the US side of the rate story that is capping the euro.

• ▼

  US-Japan currency alliance keeps selling euros Citi says the US-Japan interventions reflect an informal currency alliance, with Washington selling euros to buy yen and possibly acting again if EUR/JPY nears 185-186. Extra euro supply in the market weakens the euro against the dollar.

  It is a real, ongoing drag on the euro that readers should not overlook.

Based on 10 stories →

• ▲

  Fed rate-hike bets collapse, dollar loses its yield appeal US jobs data stayed weak and the Fed kept rates unchanged with a split committee, so traders cut the chance of a September hike to about 35% from 52% a week earlier. Lower expected US interest rates make dollar deposits less attractive, pushing EURUSD up.

  This is the main new force weakening the dollar and lifting the euro this period.

• ▲

  US Treasury buybacks and Middle East de-escalation weaken the dollar The US Treasury said it would more than double its bond buybacks to add market liquidity, which pushed the dollar down broadly and the euro up to about 1.166. Progress in Iran talks to reopen the Strait of Hormuz also cut safe-haven demand for the dollar.

  These are new events that directly weakened the dollar and pushed EURUSD to a two-month high.

• ▲

  Eurozone economy strengthens, keeping ECB hike on the table Eurozone business activity hit its highest since last November, with new orders growing fastest in 40 months and hiring rising for the first time this year. ECB official Lane said 3% inflation is too high. A stronger economy and likely ECB hike attract money into the euro.

  New eurozone data and ECB comments support the euro side of the pair.

• ▼

  Counterweight: consumers see lower inflation, and Middle East risk lingers Eurozone consumers' inflation expectations fell for a third month, which could soften the ECB's willingness to hike and cap the euro. Iran also threatened a fully offensive military posture after talks stalled, which could revive safe-haven dollar demand and push EURUSD down.

  This is the real counterweight that could stop the euro's rise, so readers get a fair picture.

Based on 24 stories →

• ▲

  ECB signals September hike, lifting euro The ECB held its key rate at 2.25% but strongly hinted at a September hike, and markets now price the deposit rate near 2.7% by year-end and 3% by 2027. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

  This is the main new force lifting the euro this period.

• ▼

  US-Japan joint intervention sells euros for yen The US and Japan jointly intervened to support the yen, selling euros to buy yen in a roughly $87 billion operation. This directly increased the supply of euros in the market, pushing the euro down against the dollar and adding geopolitical risk.

  This is a new, direct supply shock to the euro that weighs on EURUSD.

• ◆

  US data mixed: weak jobs, strong ISM and hawkish Fed Weak US jobs and soft data weakened the dollar, but strong ISM manufacturing and hawkish Fed comments later supported it. The tug-of-war between US rate-hike and rate-cut expectations keeps EURUSD volatile, with no clear direction from US data alone.

  US data is a key counterweight to the euro's rise, and its mixed nature explains the back-and-forth.

• ▲

  Eurozone GDP beats, supporting ECB hike case Eurozone second-quarter GDP rose 0.4%, beating forecasts, and business activity was strong. This supports the case for an ECB rate hike in September, making the euro more attractive to global investors and helping push EURUSD higher.

  Strong eurozone growth reinforces the ECB tightening story that lifts the euro.

Based on 24 stories →

• ▲

  Weak US jobs report kills Fed rate-hike bets, lifting euro US July payrolls unexpectedly fell by 23,000, the first drop in five months, and wage growth slowed. Traders slashed the chance of a September Fed rate hike to about 44% from 58%. Lower expected US interest rates weaken the dollar, pushing EURUSD up to a seven-week high near 1.157.

  This is the main new force this period: a weak US economy makes the dollar less attractive, directly lifting the euro.

• ▼

  US sells euros to buy yen, weakening euro The US Treasury intervened to support the yen by selling euros and buying yen, without telling the ECB first. This directly increased the supply of euros in the market, pushing the euro down against the dollar. The ECB called it shocking, raising fears of strained central-bank cooperation.

  This is a new, direct action that weakens the euro and is a real counterweight to the euro's rally.

• ▲

  Strong German trade data supports euro German trade data came in better than expected, adding to signs that Europe's largest economy is holding up. A stronger eurozone economy makes the euro more attractive to global investors, helping push EURUSD higher alongside the weak US jobs news.

  It is a new eurozone-specific factor that supports the euro and helps explain the move to a seven-week high.

Based on 8 stories →

• ▲

  Fed holds rates, dollar falls broadly The Fed kept its key rate at 3.50–3.75% for a fifth straight meeting, with only three members wanting a hike. Because US rates are not rising, the dollar lost its appeal and fell, pushing EURUSD up to about 1.143.

  A steady Fed directly weakens the dollar, the main force lifting EURUSD this period.

• ▲

  Weak US GDP and cooling PCE knock dollar to six-week low US second-quarter GDP grew only 1.5%, below the 2.0% forecast, and core PCE inflation eased to 3.3%. Slower US growth and softer inflation mean the Fed is less likely to hike, weakening the dollar and lifting the euro to a six-week high.

  Soft US data reduce expected US rates, a key driver of dollar weakness and euro strength.

• ▲

  Eurozone GDP and confidence beat, inflation accelerates to 2.9% Eurozone second-quarter GDP rose 0.4% and economic confidence hit a five-month high, while July inflation accelerated to 2.9% on higher oil. Stronger growth and sticky inflation strengthen the case for ECB rate hikes, supporting the euro.

  Better eurozone data and higher inflation raise ECB hike odds, boosting the euro's rate appeal.

• ▼

  Trump tariff threat and oil spike weigh on euro Trump threatened steep tariffs on the EU after Brussels fined Google $1 billion, and Brent crude jumped over 6% on Iran tensions. Tariffs and costlier energy hurt the eurozone economy, a counterweight that could cap the euro's gains.

  This is the main risk pulling EURUSD down, balancing the positive drivers.

Based on 6 stories →

• ▲

  ECB signals possible September hike as oil-driven inflation risks rise The ECB held its key rate at 2.25% but President Lagarde strongly hinted at a September hike, calling inflation risks tilted to the upside. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

  This is the main new monetary policy event of the period and directly supports the euro.

• ▲

  German 10-year bond yield hits 15-year high on ECB hike expectations Germany's 10-year yield surged to 3.21%, the highest since 2011, as markets priced two more ECB hikes by early 2027. Higher euro-area bond yields make euro deposits more attractive, lifting the euro against the dollar.

  Rising euro yields are a key channel through which ECB hike bets strengthen the euro.

• ▼

  Oil above $100 and Middle East attacks boost dollar safe-haven demand and Fed hike bets Houthi attacks on Saudi tankers sent Brent above $100, reigniting US inflation fears. Markets now price an 83% chance of a September Fed hike, up from 52% a week ago. Higher US rates and safe-haven flows strengthen the dollar, pushing EURUSD down.

  This is the main new force pulling EURUSD lower and is the counterweight to the ECB story.

• ◆

  SocGen warns oil spike may force ECB hikes but also sap eurozone growth Societe Generale says surging oil and gas could push the ECB to hike to 2.50% in September, but the same energy costs hurt eurozone growth. The bank sees a return above 1.1480 as a big ask, so the net effect on EURUSD is unclear.

  It fairly presents the real counterweight: higher energy prices can both help and hurt the euro.

Based on 12 stories →

• ▲

  Soft US CPI and PPI crush Fed rate-hike bets, lifting the euro US June consumer and producer inflation came in below forecasts, so traders slashed the chance of a Fed rate hike this month from 42% to 16% and for the year from 89% to 80%. Lower expected US rates weaken the dollar, pushing EURUSD up to a 3.5-week high near 1.1485.

  This is the main new force this period: softer US inflation directly reduces the dollar's rate advantage, a key driver of EURUSD.

• ◆

  Oil surge from Iran conflict cuts both ways for euro Renewed US-Iran fighting and sanctions sent oil up 9%, raising inflation fears. This could force the Fed to hike (dollar-positive) but also revives ECB hike bets (euro-positive). ING warns euro gains may stall above 1.1460 if oil keeps rising, as costlier energy hurts the eurozone economy.

  Oil is a major new factor this period, with a two-sided impact on EURUSD that explains why the euro's rally is capped.

• ▲

  ECB officials signal readiness to act, supporting euro ECB's Holzmann said no second-round inflation effects yet but the bank stands ready to act; Nagel urged caution but decisiveness if needed; Rabobank and ING note oil revives ECB hike risk. This keeps euro interest-rate appeal alive, underpinning EURUSD.

  ECB policy stance is a core driver of the euro's value versus the dollar, and this period brought fresh signals.

• ▼

  Eurozone inflation slows, ECB expected to hold rates Final June eurozone inflation was 2.8%, down from 3.2%, with core at 2.4%. Nordea expects the ECB to hold rates at its July meeting as a pause, not a pivot. Slower inflation reduces pressure to hike, limiting euro upside.

  This is a counterweight to the euro-positive ECB signals, showing why the euro isn't rising more.

Based on 21 stories →

• ▲

  ECB signals more rate hikes, supporting euro ECB minutes showed inflation will stay above target until 2027, and markets now price nearly three rate hikes. Higher euro interest rates attract global capital, pushing EURUSD up.

  This is a key new driver: ECB's hawkish stance strengthens the euro.

• ▲

  Middle East tensions weaken dollar, lift euro US-Iran ceasefire broke down, with US strikes on Iran. The dollar usually weakens on such geopolitical risk as investors avoid US assets, helping EURUSD rise.

  New escalation in Middle East tensions is a fresh factor pushing the dollar down.

• ▲

  Strong German data boosts euro German industrial production and exports rose unexpectedly in May, signaling eurozone economic resilience. A stronger economy supports the euro, pushing EURUSD higher.

  New positive economic data from Germany supports the euro.

• ◆

  Fed rate hike bets ease, but volatility may rise Weak US jobs data and stable claims reduced Fed hike odds, weakening the dollar. However, rising FX volatility and hedging demand could cause sharp swings in EURUSD.

  This shows a counterweight: while Fed bets ease, volatility risk remains.

Based on 14 stories →

• ▼

  Eurozone inflation cools, ECB hike bets fade Eurozone inflation slowed to 2.8% in June, below the 3% forecast, and German inflation also cooled. Traders cut bets on another ECB rate hike, reducing the euro's interest-rate appeal and pushing EURUSD down toward 1.1400.

  This is the main new force weakening the euro this period.

• ▲

  Weak US jobs data dents Fed hike expectations US June payrolls rose only 57,000, far below the 113,000 expected, and May's figure was revised down. This cooled bets on near-term Fed tightening, weakening the dollar and lifting the euro to a 1.5-week high above 1.1400.

  This is the main new force supporting the euro at the end of the period.

• ◆

  ECB still hawkish, but oil slump complicates ECB President Lagarde defended June's rate hike as necessary, and ING expects one more hike, supporting the euro. But lower oil prices reduce inflation pressure, and Commerzbank warns the ECB may not need to tighten much more, creating mixed signals.

  Shows the counterweight: ECB hawkishness supports the euro but may be fading.

Based on 18 stories →

• ▼

  Fed rate-hike bets drive dollar to 13-month high, euro below 1.14 The Fed under Kevin Warsh is expected to raise rates as soon as September, pulling global money into the dollar. The euro fell below 1.1400 to a one-year low near 1.1350, as higher US rates make dollar deposits more attractive than euro ones.

  This is the main force pushing EURUSD down this period.

• ▼

  Oil price collapse cuts ECB hike odds, weakening euro support Easing US-Iran tensions and restored Hormuz oil flows sent Brent crude from $115 in May to about $75. Lower energy costs reduce inflation pressure, so traders slashed the chance of a second ECB rate hike from 50% to 20%, removing a key euro support.

  This new oil-driven shift in ECB expectations is a fresh negative for the euro.

• ▼

  ECB's Lagarde downplays inflation, signaling no aggressive tightening ECB President Lagarde said the inflation shock needs only a measured response and no forceful action, even as Eurozone PMIs stay weak with German services at a 43-month low. This contrast with the hawkish Fed widens the euro-dollar interest rate gap, pushing EURUSD down.

  Lagarde's stance is a new, direct driver of euro weakness this period.

• ▲

  Dollar rally may be overdone; lower oil and weak US data spark rebound On Friday the dollar fell for a second day as lower oil and weak US consumer sentiment cooled Fed hike expectations, lifting the euro 0.43% to 1.1418. Analysts warn the dollar-positive loop may burn out, and BofA still sees euro recovery later in 2026 on German fiscal stimulus.

  This is the real counterweight that could stop or reverse the euro's fall.

Based on 24 stories →

• ▼

  Fed's hawkish turn under Warsh lifts USD, sinks EUR New Fed Chair Kevin Warsh's first meeting delivered a hawkish dot plot: nine of 19 officials now expect at least one rate hike by year-end. Higher US rates attract global capital to the dollar, pushing EURUSD down to a three-month low near 1.1416.

  This is the dominant new force this period, directly driving the euro to multi-month lows.

• ▼

  ECB hikes alone as other central banks hold The ECB raised rates and signaled more to come, but the BoE, SNB, Norges Bank and Riksbank stayed on hold. A lone hiker with weaker regional growth undermines the euro, as markets price downside risks for the euro area.

  Explains why ECB hikes are not supporting the euro, a key counterintuitive driver.

• ▲

  US-Iran peace deal briefly lifts euro Trump signed a memorandum with Iran to end the war, easing geopolitical tensions and weakening the safe-haven dollar. The euro rebounded above 1.1500, though the gain was short-lived as Fed rate expectations soon reasserted themselves.

  Shows a real counterweight to dollar strength, even if temporary.

• ◆

  Analysts warn dollar rally may be overdone ING cautioned the dollar's surge may not last, arguing the US-Iran deal removes a positive argument for the dollar and markets overestimate the chance of a Fed rate hike. This suggests EURUSD could stabilize or rebound if rate-hike bets fade.

  Provides a fair counterpoint that the dominant dollar-strength trend may reverse.

Based on 13 stories →